![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 40, 28059-28062, October 1, 1999
§ and
From the
Department of Biochemistry, Beckman Center,
Stanford University School of Medicine, Stanford, California 94305-5307 and ¶ Department of Biochemistry and Molecular Biology, University
of Miami School of Medicine, Miami, Florida 33101
Herpes simplex virus type 1 (HSV-1)1 is a member of the
herpes group of viruses, the Herpesviridiae, which includes
the important human pathogens herpes simplex virus type 2, cytomegalovirus, varicella zoster virus, Epstein-Barr virus, human
herpesviruses 6 and 7, and Kaposi's associated herpesvirus, human
herpesvirus 8 (reviewed in Ref. 1). Of these, HSV-1 has been the most
extensively studied. The HSV-1 genome is a 153-kilobase linear duplex
with 75 open reading frames. It consists of two unique regions,
UL (unique long), comprising 82% and the US
(unique short) comprising 18%, flanked by the repeated regions
a, b, and c (Fig.
1). As a consequence of recombination
through the a sequences, the HSV-1 genome actually exists as
an equimolar mixture of four isomeric forms generated by inversion of
the UL and US sequences relative to each
other.
![]()
INTRODUCTION
TOP
INTRODUCTION
Structure of Replicating DNA
Origins of DNA Replication
HSV-1 Gene Products Essential...
Attempts to Reconstitute HSV-1...
REFERENCES

View larger version (12K):
[in a new window]
Fig. 1.
Structure of the herpes simplex virus type 1 genome. A diagrammatic representation of the HSV-1 genome is
shown. The positions of the a, b, and c repeats
within the terminal repeats (TRL and TRS) and
internal repeats (IRL and IRS) and the
positions of the DNA replication origins (oriL and
oriS) are as indicated. The position and direction of
transcription of the seven essential DNA replication genes are
indicated by the arrows. The enlarged area shows the composition of a unit length a
sequence, consisting of direct repeats (DR) 1,
2, and 3 and unique (U) domains
b and c. t, terminal; n,
variable number of copies; ', inverted orientation; L, long;
S, short. This drawing is not to scale; see text for
details. (Reprinted with permission from Ref. 2.)
An interesting but poorly understood aspect of the HSV-1 life cycle, in fact, the life cycle of all the herpesviruses, is the ability to enter latency, a state in which no infectious progeny are produced and only limited transcription of viral genes occurs. Upon presentation of the appropriate stimulus, the latently infected cells enter a lytic phase with the resultant production of infectious viral particles (1).
In the lytic phase, following penetration of the nucleus, a temporally
regulated program of viral gene expression mediated by RNA polymerase
II begins. A virion protein, VP16, acts in trans together
with the cellular octamer DNA-binding protein, Oct-1, to induce the
or immediate early genes, the first set of HSV-1 genes to be
expressed. These serve as transactivators of
or early
gene expression. Their synthesis peaks at 2-4 h, postinfection. Functional
proteins are required for the synthesis of all the virally encoded proteins. Synthesis of the
class of proteins reaches peak rates 5-7 h and is detectable as early as 3 h
postinfection. The
proteins include the enzymes that are required
for replication of the viral genome: a DNA polymerase, a single-strand
DNA-binding protein, a primosome or helicase-primase, an origin-binding
protein, and a set of enzymes involved in DNA repair and in
deoxynucleotide metabolism. Homologues of these proteins are found in
virtually all herpesviruses (1, 2).
Viral DNA synthesis begins shortly after the appearance of the
proteins and is detectable as early as 3 h and continues up to
15 h postinfection, with the bulk of the DNA synthesized during
the latter part of the period. The temporal program of viral gene
expression ends with the appearance of the
or late proteins, which constitute the structural proteins of the virus (1).
| |
Structure of Replicating DNA |
|---|
|
|
|---|
As early as 0.5 h postinfection and in the absence of protein synthesis, viral DNA accumulates in the nucleus and adopts an "endless" configuration whose structure is consistent with circularization (1). Although the mechanism of genome circularization has not been established, it may involve a recombination event through the terminal repeat sequences. One clear advantage of this intermediate is that it eliminates the need for a specialized mechanism to replicate the termini.
Although there is no firm proof for the existence of theta replication intermediates that initiate at one or more of the HSV-1 origins in vivo, genome circularization is a prerequisite for viral replication, and replication requires either oriS or oriL and the action of a viral protein that possesses all the properties of an initiator protein (UL9 protein). These observations strongly suggest that HSV-1 DNA replication initiates by a theta mechanism and make it unlikely that other mechanisms, such as inter- or intramolecular recombination or transcription, all of which could potentially occur on linear DNA templates, are responsible for the initiation of HSV-1 DNA replication. At some point and by an as yet undefined mechanism, theta replication switches to the rolling circle mode, the predominant mode of HSV-1 DNA replication.
In the rolling circle mode, DNA replication generates long head-to-tail
concatamers similar to the DNA replication products observed during the
theta phase of bacteriophage
replication (3). At late times during
viral DNA replication, the products consist of branched networks of
concatamers that may arise from recombination and invading DNA
replication forks.
| |
Origins of DNA Replication |
|---|
|
|
|---|
The HSV-1 genome contains three cis-acting elements, which function as origins of DNA replication: one copy of oriL, located between the diverging UL29 and UL30 genes within UL, and two copies of oriS, located within the c sequences (Fig. 2).
Both oriS and
oriL contain large palindromes of 45 and 144 bp,
respectively, that center around an A + T region of 18 and 20 bp,
respectively. Flanking the A + T region are inverted repeats that are
binding sites for the HSV-1-encoded origin-binding protein (UL9
protein).
|
It is unclear why the HSV-1 genome contains multiple origins that
appear identical in every respect other than size and location. The
existence of two copies of oriS may be rationalized by its location in a repeated c region of the genome. However,
neither copy of oriS is essential because deletion of one
or both copies of oriS has no effect on viral DNA
replication in cultured cells (1).
| |
HSV-1 Gene Products Essential for Origin-specific DNA Replication |
|---|
|
|
|---|
The development of a transient DNA replication assay in which origin-containing plasmids are replicated by transfected HSV-1 sequences that supply trans-acting factors led to major advances in the identification of the essential HSV-1 DNA replication genes (4). This analysis permitted identification of seven HSV-1 genes all located within the UL segment of the genome that are necessary and sufficient for origin-specific DNA replication: UL5, UL8, UL9, UL29, UL30, UL42, and UL52 (Fig. 1) (5, 6). These assignments were subsequently confirmed by demonstrating that mutations in these genes abrogate viral replication (7, 8). Although the function of the UL29 (single-strand DNA-binding protein) and UL30 (DNA polymerase) gene products had already been identified, the remaining five genes encoded proteins of unknown function. These genes were subsequently correlated with proteins identified by biochemical analyses. The functions of these gene products are summarized in Table I, which also depicts the conservation of DNA replication functions in a variety of organisms/systems.
|
Origin-binding Protein (UL9 Protein)-- A search for proteins that bind to an HSV-1 origin led to the identification of an HSV-1-induced factor that could recognize sequences within oriS (9). Further purification of this sequence-specific DNA binding activity led to the identification of an 83-kDa protein that bound to two inverted repeats that flank the A + T region, within oriS, designated Boxes I and II (Fig. 2) (10). In oriL the two Box I sites are flanked by homologous sequences designated Box III, which differ from Box I by only 1 residue but act as low affinity recognition sites for the UL9 protein. In oriS there is only one copy of Box III, 5' to Box I. Subsequently, it was demonstrated that the origin-binding protein is the product of the UL9 gene (11). The UL9 gene encodes an 851-amino acid polypeptide (UL9 protein) with a calculated mass of 94,246 Da (12). Amino acid sequence analysis of the UL9 protein led to the identification of conserved ATP binding and DNA helicase motifs (13, 14) that have been shown to be essential for viral replication (15, 16). The sequence-specific DNA binding activity of the UL9 protein resides in the C-terminal 317 amino acids (16). Expression of the 37-kDa C-terminal DNA-binding domain has a dominant negative effect on viral replication, presumably because of its ability to occupy the origin nonproductively (16, 17). Although the UL9 protein can bind to its recognition sequence as a homodimer, only one of the two monomers contacts the DNA (18). The dimerization of UL9 protein is mediated through the N-terminal part of the protein, presumably through a leucine zipper motif encompassing residues 150-171 (19, 20). The binding of UL9 protein to oriS appears to be enhanced by nucleoside triphosphates (21).
In addition to its sequence-specific DNA binding activity, the
UL9 protein possesses DNA-stimulated nucleoside triphosphatase and
nonspecific 3'
5'-DNA helicase activities (22-25). ICP8, the HSV-1
single-strand DNA-binding protein, interacts with the extreme C
terminus of the UL9 protein, greatly stimulating its DNA-dependent ATPase and DNA helicase activities (25). In
the absence of ICP8 the UL9 protein is non-processive. ICP8 appears to
stimulate the UL9 protein by preventing its dissociation from the DNA
(25, 26).
The UL9 protein, together with ICP8, can unwind specifically Box I of
oriS if an appropriately oriented 3' single-stranded tail
of at least 18 nucleotides (the binding site size for ICP8; see below)
is attached to Box I (27). This finding suggests that a complex
consisting of the UL9 protein and ICP8 bound to appropriately oriented
single-stranded DNA constitutes the specific helicase that can separate
the two strands, permitting entry of the DNA replication
machinery. The single-stranded DNA-binding site for ICP8 in
oriS may be provided by the A + T sequence that links Boxes
I and II. Because of its relatively weak hydrogen bonding, this
sequence may be easily unwound, either by the UL9 protein itself or as
a consequence of the initiation of transcription at the promoters that
flank the origin. This mode of unwinding of an HSV-1 origin by the UL9-protein-ICP8-single-stranded DNA complex
differs from that seen with the SV40 T antigen, in which the T antigen
itself is the origin-specific helicase and the SSB plays a purely
passive role binding the single strands generated by helicase
action and thereby preventing their reannealing (28).
|
Single-strand DNA-binding Protein, ICP8-- ICP8 is the product of the UL29 gene (29) and consists of 1196 amino acids with a calculated molecular mass of 128,342 Da.
ICP8 binds single-stranded DNA rapidly and cooperatively and with at least 5-fold greater affinity than double-stranded DNA (30, 31). Examination of ICP8 binding to single-stranded DNA, by electron microscopy and negative staining, showed regular protein-DNA filaments in which the DNA is held in an extended configuration (32, 33). Estimates of the DNA-binding site size for ICP8 fall in the range of one ICP8 to 12-22 nucleotides (34-36), values that are in agreement with a site size of 15-18 nucleotides estimated by electron microscopy (33).
Primosome (DNA Helicase-Primase)-- The HSV-1-encoded primosome consists of three subunits with molecular masses of 98,710, 79,291, and 114,416 Da, the products of the UL5, UL8, and UL52 genes, respectively (6).
The holoenzyme consists of a 1:1:1 association of the UL5, UL8, and UL52 gene products, with a native molecular mass of ~270 kDa (37, 38). A subassembly that consists of the UL5 and UL52 subunits retains DNA-dependent ATPase, helicase, and primase activities and therefore constitutes the core enzyme (39, 40). In contrast, the UL8 protein lacks detectable enzymatic or DNA binding activities (40, 41). Under the appropriate conditions of Mg2+ concentration and ionic strength the helicase activity of the helicase-primase can unwind 60-65 bp/s, a value consistent with the rate of 50 bp/s estimated for the rate of fork movement in vivo during replication of pseudorabies virus, another herpesvirus (42).
Residues 610-636 of the UL52 protein contain a proposed divalent metal
binding motif that is conserved in DNA polymerases and primases (43,
44). Site-directed mutagenesis of this motif inactivates the primase
activity of the mutant holoenzyme in vitro and abolishes
origin-specific DNA replication in vivo, indicating that it
comprises the primase active site. The products of primase action are
oligoribonucleotides that are 6-13 bases in length (45, 46). With
single-stranded
X174 DNA as template, the primase exhibits sequence
specificity. The preferred template sequence was mapped to
3'-AGCCCTCCCA, directing the synthesis of a 10-mer
oligoribonucleotide, starting at the underlined C residue (48).
The UL8 protein stimulates primer synthesis by the UL5/52 subassembly (47-49). Thus, although UL8 protein has no effect on the Km(DNA) (15 µM nucleotides) of the subassembly, it increases the rate of primer synthesis approximately 3-fold (47). The UL8 protein is also required for optimal DNA helicase and DNA-dependent ATPase activities of the enzyme in the presence of ICP8-coated DNA templates (49, 50). It therefore resembles the helicase/primase loading factors seen in other systems (see Table I). The E. coli single-strand DNA-binding protein cannot substitute for ICP8, suggesting a specific interaction between ICP8 and the UL8 protein. Surface plasmon resonance measurements did, in fact, demonstrate an interaction between ICP8 and the U5/52/8 heterotrimer but not with the UL5/52 subassembly or the UL8 protein alone (49).
DNA Polymerase--
The HSV-1 DNA polymerase has been intensively
studied, both as a model eukaryotic DNA polymerase and as a target for
antiviral drugs. It is a 1235-amino acid, 136,413-Da protein that is
encoded by the UL30 gene (29, 51-53). The UL30 protein
exhibits significant sequence similarity to other viral and
cellular DNA polymerases including human DNA polymerase
-primase, Saccharomyces cerevisiae DNA polymerase
,
E. coli DNA polymerase I, and the bacteriophage T4 DNA
polymerase (54, 55).
The HSV-1 DNA polymerase purified from virus-infected cells exists as a
heterodimer in which the UL30 protein is associated with a 65-kDa
protein (56-58). The 65-kDa protein is the product of the
UL42 gene which encodes a 488-amino acid, 51,154-Da
phosphoprotein that possesses double-strand DNA binding activity (6,
59). The interaction between the UL30 and UL42 proteins occurs with an
association constant of 1 × 108
M
1 (60) and has been shown to be
essential for viral replication (61).
The HSV-1 DNA polymerase possesses 3'
5'-exonuclease activity that
is intrinsic to the UL30 subunit (62, 63). The exonuclease is active
under conditions that are optimal for deoxynucleotide polymerization
and can act on a variety of DNA substrates including gapped DNA, DNA
hairpin structures, and single-stranded oligodeoxyribonucleotides (63).
In the absence of dNTPs, the 3'
5'-exonuclease is twice as active
at removing 3'-unpaired deoxynucleotides as paired deoxynucleotides. In
the presence of all four dNTPs, there is no detectable 3'
5'-exonuclease on paired deoxynucleotides, presumably because of
continuous polymerization. In contrast unpaired deoxynucleotides are
completely removed (63). Consequently, the 3'
5'-exonuclease serves
as a proofreading activity to ensure high fidelity of DNA replication.
In addition to its 3'
5'-exonuclease, the HSV-1 DNA polymerase has
a RNase H activity that presumably serves to remove RNA primers during
the processing of Okazaki fragments (58).
The UL42 protein acts to increase the processivity of the UL30 DNA
polymerase (36, 64, 65). It is therefore a functional homologue of the
DNA polymerase processivity enhancing factors, which include the
subunit of E. coli DNA polymerase III holoenzyme, the
eukaryotic proliferating cell nuclear antigen, and bacteriophage T4
gene 45 protein (28, 66) (see Table I). These proteins form a ring that
encircles the DNA duplex and interact with their cognate DNA polymerase
to prevent dissociation of the enzyme from the primer-template, thereby
ensuring high processivity of deoxynucleotide polymerization. However,
these DNA polymerase clamps lack DNA binding activity, and their
assembly on the DNA is mediated by another set of proteins, the clamp
loaders. In contrast, the HSV-1 DNA polymerase is tethered to the DNA
by the double-strand DNA binding activity of the UL42 protein itself.
This model is supported by the finding that stimulation of DNA
polymerase activity requires the DNA binding activity of the UL42
protein (64, 65).
Numerous nucleotide analogues (9-(2-hydroxyethoxymethyl)
guanosine 5'-triphosphate (acyclovir triphosphate),
9-
-D-arabinofuranosyladenosine 5'-triphosphate (araATP),
aphidicolin, (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate) and pyrophosphate analogues (phosphonoacetate, phosphonoformate, oxalate) have been examined for their ability to
inhibit viral replication in vivo and to inhibit selectively the HSV-1 DNA polymerase in vitro. This has led to the
development of several antiviral drugs, notably gancyclovir and
acyclovir, which are of significant therapeutic value (52).
In addition to ICP8, the DNA polymerase-UL42 complex, the UL9 protein,
and the DNA helicase-primase, all of which are essential for HSV-1 DNA
replication, the HSV-1 genome encodes a set of enzymes whose function
is not required for its replication in cultured cells. They undoubtedly
serve some function in the viral life cycle. These include an alkaline
endo-exonuclease that exhibits 5'
3'-exonuclease activity (UL12
protein) and may thus participate in the completion of lagging-strand
DNA synthesis, a uracil DNA glycosylase, a deoxyuridine triphosphatase,
a thymidine kinase, and a ribonucleotide reductase (2).
| |
Attempts to Reconstitute HSV-1 DNA Replication in Vitro |
|---|
|
|
|---|
As described previously, studies of HSV-1 DNA replication in
vivo have demonstrated that the linear 153-kilobase pair genome circularizes shortly after infection of susceptible host cells and then
enters a rolling circle mode of DNA replication generating branched
concatameric DNA, which is then cleaved and packaged as unit-length
molecules. The existence of specific origins of replication
oriS or oriL as well as a protein (the UL9
protein) with helicase activity that binds the origins with high
affinity suggests that a theta mode of DNA replication precedes the
rolling circle phase (Fig. 3). A bipartite mode of DNA replication of this kind has been observed for bacteriophage
(3). Although, as
noted above, rolling circle replication of the HSV-1 genome as well as
of plasmids into which an HSV-1 origin has been inserted has been
observed in vivo, there is as yet no compelling evidence in vivo for a theta mode of replication.
Numerous attempts have been made to observe origin (oriS or oriL)-dependent DNA replication in vitro. None has thus far been successful.
In contrast to the inability to reconstitute the theta model of HSV-1 DNA replication, rolling circle replication promoted by extracts of HSV-1-infected cells has been achieved. The first demonstration of rolling circle replication made use of an artificial replication fork consisting of M13 single-stranded DNA to which a complementary oligonucleotide with an unpaired 5' single-stranded tail had been annealed. Rolling circle replication was observed both with crude extracts of HSV-1-infected cells and with a partially purified fraction containing the HSV-1 DNA polymerase and the UL5 and UL52 subunits of the DNA helicase-primase. ICP8 stimulated the reaction but was not essential (67).
In a second approach, a high molecular mass complex (Mr > 106) was isolated by gel filtration and ion-exchange chromatography from extracts of insect (Sf9) cells that had been multiply infected with baculoviruses recombinant for the seven HSV-1 genes that are required for its replication. This complex, which consisted of the HSV-1 DNA polymerase, ICP8, and DNA helicase-primase, could promote the rolling circle replication of circular plasmid templates to generate concatameric DNA molecules up to four times unit length as judged by gel electrophoresis and electron microscopy. Neither the UL9 protein nor an HSV-1 origin was required, and in fact, the presence of oriS within the plasmid inhibited DNA replication in the presence, but not the absence, of the UL9 protein (68).
Whole-cell extracts of HSV-1-infected human cells (293 cells) can also
promote the rolling circle replication of plasmid templates in a
reaction that closely resembles that observed with the high molecular
weight complex isolated from the baculovirus-infected Sf9 cells
(69). Preliminary evidence suggests that a similar enzyme complex is
present in the HSV-1-infected 293 cells. Although the rate of fork
movement in these reactions has not been accurately determined, it
appeared to approach the in vivo rate cited above. However,
the efficiency of the reaction is very low (1-2% of the template
molecules replicated) for both the complex obtained from the
baculovirus-infected Sf9 cells and the extract of HSV-1-infected 293 cells. The form of the plasmid DNA that serves as the template for
rolling circle replication is not known, and the small proportion of
the template molecules replicated may reflect the low level of the
appropriate template that is generated by either the enzyme complex or
the crude extract. Possibly a recombinational event analogous to that
which appears to be involved in the switch from theta to rolling circle
replication in bacteriophage
may be required (3).
In summary, HSV-1 is a large (153 kilobase pairs), double-stranded DNA
virus whose genome contains multiple, redundant origins of replication.
HSV-1 encodes a repertoire of proteins that, with the exception of a
DNA ligase and topoisomerase, should suffice to initiate and sustain
DNA replication. The current view is that following circularization of
the linear HSV-1 genome, replication proceeds initially by
origin-dependent theta followed by
origin-independent rolling circle DNA replication. A host DNA
polymerase, DNA polymerase
-primase, may function during the
theta phase (70) (Fig. 3). Finally, the functions of the
HSV-1 DNA replication proteins resemble those found in other organisms,
further indicating strong conservation in the mechanisms of DNA replication.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999. The work in the authors' laboratories is supported by National Institutes of Health Grants AI26538 (to I. R. L.) and AI38335 (to P. E. B.).
§ To whom correspondence should be addressed. Tel.: 650-723-6164; Fax: 650-723-6783; E-mail: blehman@cmgm.stanford.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HSV-1, herpes simplex virus type 1; bp, base pairs.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Roizman, B., and Sears, A. E. (1996) in Fields Virology (Fields, B. N. , Knipe, D. M. , and Howley, P. M., eds) , pp. 2231-2295, Lippincott-Raven, Philadelphia, PA |
| 2. | Boehmer, P. E., and Lehman, I. R. (1997) Annu. Rev. Biochem. 66, 347-384[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Stahl, F. W., and Stahl, M. M. (1971) in The Bacteriophage Lambda (Hershey, A. D., ed) , pp. 195-210, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 4. |
Challberg, M. D.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
9094-9098 |
| 5. |
Wu, C. A.,
Nelson, N. J.,
McGeoch, D. J.,
and Challberg, M. D.
(1988)
J. Virol.
62,
435-443 |
| 6. |
McGeoch, D. J.,
Dalrymple, M. A.,
Dolan, A.,
McNab, D.,
Perry, L. J.,
Taylor, P.,
and Challberg, M. D.
(1988)
J. Virol.
62,
444-453 |
| 7. |
Zhu, L. A.,
and Weller, S. K.
(1992)
J. Virol.
66,
458-468 |
| 8. |
Johnson, P. A.,
Best, M. G.,
Friedmann, T.,
and Parris, D. S.
(1991)
J. Virol.
65,
700-710 |
| 9. |
Elias, P.,
O'Donnell, M. E.,
Mocarski, E. S.,
and Lehman, I. R.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
6322-6326 |
| 10. |
Elias, P.,
and Lehman, I. R.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2959-2963 |
| 11. |
Olivo, P. D.,
Nelson, N. J.,
and Challberg, M. D.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
5414-5418 |
| 12. |
McGeoch, D. J.,
Dalrymple, M. A.,
Davison, A. J.,
Dolan, A.,
Frame, M. C.,
McNab, D.,
Perry, L. J.,
Scott, J. E.,
and Taylor, P.
(1988)
J. Gen. Virol.
69,
1531-1574 |
| 13. | Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) EMBO J. 1, 945-951[Medline] [Order article via Infotrieve] |
| 14. |
Gorbalenya, A. E.,
Koonin, E. V.,
Donchenko, A. P.,
and Blinov, V. M.
(1989)
Nucleic Acids Res.
17,
4713-4730 |
| 15. |
Martinez, R.,
Shao, L.,
and Weller, S. K.
(1992)
J. Virol.
66,
6735-6746 |
| 16. | Stow, N. D., Hammarsten, O., Arbuckle, M. I., and Elias, P. (1993) Virology 196, 413-418[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Perry, H. C., Hazuda, D. J., and McClements, W. L. (1993) Virology 193, 73-79[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Lee, S. S-K.,
and Lehman, I. R.
(1999)
J. Biol. Chem
274,
18613-18617 |
| 19. |
Elias, P.,
Gustafsson, C. M.,
Hammarsten, O.,
and Stow, N. D.
(1992)
J. Biol. Chem.
267,
17424-17429 |
| 20. |
Deb, S.,
and Deb, S. P.
(1991)
J. Virol.
65,
2829-2838 |
| 21. |
Gustafsson, C. M.,
Falkenberg, M.,
Simonsson, S.,
Valadi, H.,
and Elias, P.
(1995)
J. Biol. Chem.
270,
19028-19034 |
| 22. |
Bruckner, R. C.,
Crute, J. J.,
Dodson, M. S.,
and Lehman, I. R.
(1991)
J. Biol. Chem.
266,
2669-2674 |
| 23. |
Fierer, D. S.,
and Challberg, M. D.
(1992)
J. Virol.
66,
3986-3995 |
| 24. |
Dodson, M. S.,
and Lehman, I. R.
(1993)
J. Biol. Chem.
268,
1213-1219 |
| 25. |
Boehmer, P. E.,
Dodson, M. S.,
and Lehman, I. R.
(1993)
J. Biol. Chem.
268,
1220-1225 |
| 26. |
Boehmer, P. E.,
and Lehman, I. R.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8444-8448 |
| 27. |
Lee, S. S-K.,
and Lehman, I. R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
94,
2838-2842 |
| 28. | Borowiec, J. A., and DePamphilis, M. L. (eds) (1996) DNA Replication in Eukaryotic Cells , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 29. |
Quinn, J. P.,
and McGeoch, D. J.
(1985)
Nucleic Acids Res.
13,
8143-8163 |
| 30. |
Ruyechan, W. T.
(1983)
J. Virol.
46,
661-666 |
| 31. |
Lee, C. K.,
and Knipe, D. M.
(1985)
J. Virol.
54,
731-738 |
| 32. |
Ruyechan, W. T.,
and Weir, A. C.
(1984)
J. Virol.
52,
727-733 |
| 33. | Makhov, A. M., Boehmer, P. E., Lehman, I. R., and Griffith, J. D. (1996) J. Mol. Biol. 258, 789-799[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Boehmer, P. E.,
and Lehman, I. R.
(1993)
J. Virol.
67,
711-715 |
| 35. |
Dutch, R. E.,
and Lehman, I. R.
(1993)
J. Virol.
67,
6945-6949 |
| 36. |
Hernandez, T. R.,
and Lehman, I. R.
(1990)
J. Biol. Chem.
265,
11227-11232 |
| 37. |
Crute, J. J.,
Tsurumi, T.,
Zhu, L. A.,
Weller, S. K.,
Olivo, P. D.,
Challberg, M. D.,
Mocarski, E. S.,
and Lehman, I. R.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
2186-2189 |
| 38. |
Dodson, M. S.,
Crute, J. J.,
Bruckner, R. C.,
and Lehman, I. R.
(1989)
J. Biol. Chem.
264,
20835-20838 |
| 39. |
Calder, J. M.,
and Stow, N. D.
(1990)
Nucleic Acids Res.
18,
3573-3578 |
| 40. |
Dodson, M. S.,
and Lehman, I. R.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1105-1109 |
| 41. |
Parry, M. E.,
Stow, N. D.,
and Marsden, H. S.
(1993)
J. Gen. Virol.
74,
607-612 |
| 42. |
Falkenberg, M.,
Elias, P.,
and Lehman, I. R.
(1998)
J. Biol. Chem.
273,
32154-32157 |
| 43. |
Klinedinst, D. K.,
and Challberg, M. D.
(1994)
J. Virol.
68,
3693-3701 |
| 44. |
Dracheva, S.,
Koonin, E. V.,
and Crute, J. J.
(1995)
J. Biol. Chem.
270,
14148-14153 |
| 45. |
Crute, J. J.,
and Lehman, I. R.
(1991)
J. Biol. Chem.
266,
4484-4488 |
| 46. |
Sherman, G.,
Gottlieb, J.,
and Challberg, M. D.
(1992)
J. Virol.
66,
4884-4892 |
| 47. |
Tenney, D. J.,
Hurlburt, W. W.,
Micheletti, P. A.,
Bifano, M.,
and Hamatake, R. K.
(1994)
J. Biol. Chem.
269,
5030-5035 |
| 48. |
Tenney, D. J.,
Schaeffer, A. K.,
Hurlburt, W. W.,
Bifano, M.,
and Hamatake, R. K.
(1995)
J. Biol. Chem.
270,
9129-9136 |
| 49. |
Falkenberg, M.,
Bushnell, D. A.,
Elias, P.,
and Lehman, I. R.
(1997)
J. Biol. Chem.
272,
22766-22770 |
| 50. |
Tanguy Le Gac, N.,
Villani, G.,
Hoffman, J.-S.,
and Boehmer, P. E.
(1996)
J. Biol. Chem.
271,
21645-21651 |
| 51. | Purifoy, D. J., Lewis, R. B., and Powell, K. L. (1977) Nature 269, 621-623[CrossRef][Medline] [Order article via Infotrieve] |
| 52. |
Gibbs, J. S.,
Chiou, H. C.,
Hall, J. D.,
Mount, D. W.,
Retondo, M. J.,
Weller, S. K.,
and Coen, D. M.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
7969-7973 |
| 53. | Hall, J. D., Gibbs, J. S., Coen, D. M., and Mount, D. W. (1986) DNA 5, 281-288[Medline] [Order article via Infotrieve] |
| 54. |
Digard, P.,
and Coen, D. M.
(1990)
J. Biol. Chem.
265,
17393-17396 |
| 55. | Blanco, L., Bernad, A., Blasco, M. A., and Salas, M. (1991) Gene (Amst.) 100, 27-38[CrossRef][Medline] [Order article via Infotrieve] |
| 56. |
Vaughan, P. J.,
Purifoy, D. J. M.,
and Powell, K. L.
(1985)
J. Virol.
53,
501-508 |
| 57. |
Gallo, M. L.,
Jackwood, D. H.,
Murphy, M.,
Marsden, H. S.,
and Parris, D. S.
(1988)
J. Virol.
62,
2874-2883 |
| 58. |
Crute, J. J.,
and Lehman, I. R.
(1989)
J. Biol. Chem.
264,
19266-19270 |
| 59. |
Parris, D. S.,
Cross, A.,
Haarr, L.,
Orr, A.,
Frame, M. C.,
Murphy, M.,
McGeoch, D. J.,
and Marsden, H. S.
(1988)
J. Virol.
62,
818-825 |
| 60. |
Hamatake, R. K.,
Bifano, M.,
Tenney, D. J.,
Hurlburt, W. W.,
and Cordingley, M. G.
(1993)
J. Gen. Virol.
74,
2181-2189 |
| 61. |
Digard, P.,
Bebrin, W. R.,
Weisshart, K.,
and Coen, D. M.
(1993)
J. Virol.
67,
398-406 |
| 62. | Knopf, K. W. (1979) Eur. J. Biochem. 98, 231-244[Medline] [Order article via Infotrieve] |
| 63. |
O'Donnell, M. E.,
Elias, P.,
and Lehman, I. R.
(1987)
J. Biol. Chem.
262,
4252-4259 |
| 64. |
Gallo, M. L.,
Dorsky, D. I.,
Crumpacker, C. S.,
and Parris, D. S.
(1989)
J. Virol.
63,
5023-5029 |
| 65. |
Gottlieb, J.,
Marcy, A. I.,
Coen, D. M.,
and Challberg, M. D.
(1990)
J. Virol.
64,
5976-5987 |
| 66. | Kong, X. P., Onrust, R., O'Donnell, M. E., and Kuriyan, J. (1992) Cell 69, 425-437[CrossRef][Medline] [Order article via Infotrieve] |
| 67. |
Rabkin, S. D.,
and Hanlon, B.
(1990)
J. Virol.
64,
4957-4967 |
| 68. |
Skaliter, R.,
and Lehman, I. R.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10665-10669 |
| 69. | Skaliter, R., Makhov, A. M., Griffith, J. D., and Lehman, I. R. (1996) J. Virol. 70, 1132-1136[Abstract] |
| 70. |
Lee, S. S.-K.,
Dong, Q.,
Wang, T. S. F.,
and Lehman, I. R.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7882-7886 |
This article has been cited by other articles:
![]() |
A. Calle, I. Ugrinova, A. L. Epstein, P. Bouvet, J.-J. Diaz, and A. Greco Nucleolin Is Required for an Efficient Herpes Simplex Virus Type 1 Infection J. Virol., May 15, 2008; 82(10): 4762 - 4773. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Link, L. A. Silva, and P. A. Schaffer Cathepsin B Mediates Cleavage of Herpes Simplex Virus Type 1 Origin Binding Protein (OBP) To Yield OBPC-1, and Cleavage Is Dependent upon Viral DNA Replication J. Virol., September 1, 2007; 81(17): 9175 - 9182. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, C. M. Livingston, S. D. Carrington-Lawrence, P. Bai, and S. K. Weller A Mutation in the Human Herpes Simplex Virus Type 1 UL52 Zinc Finger Motif Results in Defective Primase Activity but Can Recruit Viral Polymerase and Support Viral Replication Efficiently J. Virol., August 15, 2007; 81(16): 8742 - 8751. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Muylaert and P. Elias Knockdown of DNA Ligase IV/XRCC4 by RNA Interference Inhibits Herpes Simplex Virus Type I DNA Replication J. Biol. Chem., April 13, 2007; 282(15): 10865 - 10872. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, J. D. Knafels, J. S. Chang, G. A. Waszak, E. T. Baldwin, M. R. Deibel Jr., D. R. Thomsen, F. L. Homa, P. A. Wells, M. C. Tory, et al. Crystal Structure of the Herpes Simplex Virus 1 DNA Polymerase J. Biol. Chem., June 30, 2006; 281(26): 18193 - 18200. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Slanina, S. Weger, N. D. Stow, A. Kuhrs, and R. Heilbronn Role of the Herpes Simplex Virus Helicase-Primase Complex during Adeno-Associated Virus DNA Replication. J. Virol., June 1, 2006; 80(11): 5241 - 5250. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Pomeranz, A. E. Reynolds, and C. J. Hengartner Molecular Biology of Pseudorabies Virus: Impact on Neurovirology and Veterinary Medicine Microbiol. Mol. Biol. Rev., September 1, 2005; 69(3): 462 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shirata, A. Kudoh, T. Daikoku, Y. Tatsumi, M. Fujita, T. Kiyono, Y. Sugaya, H. Isomura, K. Ishizaki, and T. Tsurumi Activation of Ataxia Telangiectasia-mutated DNA Damage Checkpoint Signal Transduction Elicited by Herpes Simplex Virus Infection J. Biol. Chem., August 26, 2005; 280(34): 30336 - 30341. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-M. Borst and M. Messerle Analysis of Human Cytomegalovirus oriLyt Sequence Requirements in the Context of the Viral Genome J. Virol., March 15, 2005; 79(6): 3615 - 3626. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Geoffroy, A. L. Epstein, E. Toublanc, P. Moullier, and A. Salvetti Herpes Simplex Virus Type 1 ICP0 Protein Mediates Activation of Adeno-Associated Virus Type 2 rep Gene Expression from a Latent Integrated Form J. Virol., October 15, 2004; 78(20): 10977 - 10986. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Murata, M. S. Dodson, and J. D. Hall A Human Cellular Protein Activity (OF-1), Which Binds Herpes Simplex Virus Type 1 Origin, Contains the Ku70/Ku80 Heterodimer J. Virol., July 15, 2004; 78(14): 7839 - 7842. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Grose, S. Tyler, G. Peters, J. Hiebert, G. M. Stephens, W. T. Ruyechan, W. Jackson, J. Storlie, and G. A. Tipples Complete DNA Sequence Analyses of the First Two Varicella-Zoster Virus Glycoprotein E (D150N) Mutant Viruses Found in North America: Evolution of Genotypes with an Accelerated Cell Spread Phenotype J. Virol., July 1, 2004; 78(13): 6799 - 6807. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Stracker, G. D. Cassell, P. Ward, Y.-M. Loo, B. van Breukelen, S. D. Carrington-Lawrence, R. K. Hamatake, P. C. van der Vliet, S. K. Weller, T. Melendy, et al. The Rep Protein of Adeno-Associated Virus Type 2 Interacts with Single-Stranded DNA-Binding Proteins That Enhance Viral Replication J. Virol., January 1, 2004; 78(1): 441 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Heilbronn, M. Engstler, S. Weger, A. Krahn, C. Schetter, and M. Boshart ssDNA-dependent colocalization of adeno-associated virus Rep and herpes simplex virus ICP8 in nuclear replication domains Nucleic Acids Res., November 1, 2003; 31(21): 6206 - 6213. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Nimonkar and P. E. Boehmer Reconstitution of recombination-dependent DNA synthesis in herpes simplex virus 1 PNAS, September 2, 2003; 100(18): 10201 - 10206. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Marintcheva and S. K. Weller Existence of Transdominant and Potentiating Mutants of UL9, the Herpes Simplex Virus Type 1 Origin-Binding Protein, Suggests that Levels of UL9 Protein May Be Regulated during Infection J. Virol., September 1, 2003; 77(17): 9639 - 9651. [Abstract] [Full Text] [PDF] |
||||
|
|